Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD44 | P16070 | 2/20 | 0.47 |
| ▸ | PNMT | P11086 | 5/20 | 0.45 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.40 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.40 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.40 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL16037813 | 0.98 | CD44 (0.46) | CD44PNMTACHEMAOBADRA2A | |
| SCHEMBL23036826 | 0.84 | PNMT (0.57) | CD44PNMTMAOBADRA2AADRA2B | |
| SCHEMBL30578819 | 0.84 | PNMT (0.57) | CD44PNMTMAOBADRA2AADRA2B | |
| SCHEMBL9197082 | 0.81 | PNMT (0.37) | PNMTACHE | |
| SCHEMBL16038610 | 0.81 | HTR2C (0.45) | CD44PNMTMAOBADRA2AADRA2B | |
| SCHEMBL3057424 | 0.81 | CD44 (0.44) | CD44PNMTMAOBADRA2AADRA2B | |
| SCHEMBL23683891 | 0.81 | PNMT (0.46) | CD44PNMTMAOBADRA2AADRA2B | |
| SCHEMBL22993478 | 0.81 | HTR2A (0.50) | CD44PNMTADRA2AADRA2BADRA2C | |
| Bromide SCHEMBL17583924 | 0.79 | HTR2A (0.49) | CD44PNMTADRA2AADRA2BADRA2C | |
| Hydrochloric Acid SCHEMBL16039224 | 0.79 | HTR2C (0.44) | CD44PNMTMAOBADRA2AADRA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9713615-B2 | Tetrahydroisoquinolin-2-yl-(quinazolin-4-yl)methanone compounds | REXAHN PHARMACEUTICALS, INC. (US) | 2017-07-25 | — | — | US | disclosed |
| US-20160136166-A1 | TETRAHYDROISOQUINOLIN-2-YL-(QUINAZOLIN-4-YL)METHANONE COMPOUNDS | Ocuphire Pharma, Inc. | 2016-05-19 | — | — | US | disclosed |
| EP-2970203-A1 | TETRAHYDROISOQUINOLIN-2-YL-(QUINAZOLIN-4-YL) METHANONE COMPOUNDS AS CANCER CELL GROWTH INHIBITORS | Rexahn Pharmaceuticals, Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| US-9193707-B2 | Tetrahydroisoquinolin-2-yl-(quinazolin-4-yl)methanone compounds | REXAHN PHARMACEUTICALS, INC. (US) | 2015-11-24 | — | — | US | disclosed |
| WO-2014143960-A1 | TETRAHYDROISOQUINOLIN-2-YL-(QUINAZOLIN-4-YL) METHANONE COMPOUNDS AS CANCER CELL GROWTH INHIBITORS | REXAHN PHARMACEUTICALS, INC. (US) | 2014-09-18 | — | — | WO | disclosed |
| US-20140275129-A1 | TETRAHYDROISOQUINOLIN-2-YL-(QUINAZOLIN-4-YL)METHANONE COMPOUNDS | REXAHN PHARMACEUTICALS, INC. (US) | 2014-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140275129-A1 | TETRAHYDROISOQUINOLIN-2-YL-(QUINAZOLIN-4-YL)METHANONE COMPOUNDS | HRAS, RECQL, CDK4 | CD44 4882/4885PNMT 2145/4885ACHE 4617/4885 |
| US-20160136166-A1 | TETRAHYDROISOQUINOLIN-2-YL-(QUINAZOLIN-4-YL)METHANONE COMPOUNDS | HRAS, RECQL, CDK4 | CD44 4882/4885PNMT 2145/4885ACHE 4617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.